Antimicrobials
Fluconazole

Fluconazole

Low
Excellent

Spectrum of Activity

Dosing

General Information

HEALTH CANADA APPROVED

  • Oropharyngeal and esophageal candidiasis. Also serious systemic Candida infections including urinary tract infections, peritonitis, and pneumonia
  • Cryptococcal meningitis
  • Prevention of the recurrence of cryptococcal meningitis in patients with AIDS. Typically dosed PO
  • Abnormal baseline liver function tests or those who develop abnormal liver function tests; monitor for signs of severe hepatic damage
  • Patients with risk factors for development of prolonged QTc interval (eg structural heart disease, bradycardia, electrolyte abnormalities, hepatic impairment)
  • Is an inhibitor of cytochrome P450 isoenzymes including CYP2C19 (strong), CYP2C9 (moderate), CYP3A4 (moderate); Interacts with many drugs - consult pharmacy or specialised on-line references for more information. Review drug profile at time of initiation and with any change in medication regimen
  • Drugs that may prolong the QTc interval: possible additive effect

RECOMMENDED

  • Baseline liver function tests eg AST, ALT, alkaline phosphatase and total bilirubin
  • Consider QTc monitoring if concomitant drugs affecting the interval or elevated baseline measurement

IM or subcutaneous administration: no information available at this time

Antimicrobial class: Triazole antifungal

Pregnancy category: C

Average serum half life: 20 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic